Beta-O2 Technologies Overview

  • Founded
  • 2004
  • Status
  • Private
  • Employees
  • 24
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $32.5M
Latest Deal Amount
  • Investors
  • 9

Beta-O2 Technologies General Information


Developer of a bio-artificial pancreas designed to help cure Type 1 diabetes (TID). The company's artificial pancreas is implantable and provides a viable and safe environment for pancreatic IOL inside a subcutaneously implanted bioreactor which helps the cells to thrive, function like native IOL thus providing the body with the two essential hormones at the correct ratio and solving the challenges of islet transplantation like adequate oxygen supply by proactively supplying oxygen to contained cells and full immune-protection, enabling diabetic patients to be freed from risky and morbidity-inducing immune-suppressive drugs therapy and use the technology to maintain any future source of hormones secreting cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
  • 11 Amal Street
  • POB 11793
  • Rosh-Haayin 4809900
  • Israel
+972 000-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Beta-O2 Technologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC $32.5M 000.00 Completed Generating Revenue
4. Later Stage VC 30-Mar-2015 000 Completed Clinical Trials - Phase 1
3. Grant 10-Sep-2014 00000 000 Completed Startup
2. Early Stage VC 06-Feb-2007 $5M $7M Completed Startup
1. Seed Round 08-Mar-2004 $2M $2M Completed Startup
To view Beta-O2 Technologies’s complete valuation and funding history, request access »

Beta-O2 Technologies Executive Team (13)

Name Title Board Seat Contact Info
Amir Lichter Chief Executive Officer & Board Member
Avi Rotem Ph.D Chief Technology Officer
Uriel Barkai Ph.D Chief Scientific Officer
Lone Wolinsky Chief Engineer
Baruch Zimerman Ph.D Trials Manager
You’re viewing 5 of 13 executive team members. Get the full list »

Beta-O2 Technologies Board Members (12)

Name Representing Role Since
Abraham Ludomirski MD SCP Vitalife Partners Director 000 0000
Amir Lichter Beta-O2 Technologies Chief Executive Officer & Board Member 000 0000
Eli Frydman Ph.D Self Board Member 000 0000
Hongkui Deng Ph.D Beta-O2 Technologies Board Member 000 0000
Ilan Lior Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Beta-O2 Technologies Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Beta-O2 Technologies Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Oxen9 Venture Capital Minority 000 0000 000000 0
Sherpa Innoventures Venture Capital Minority 000 0000 000000 0
Aurum Ventures MKI Venture Capital Minority 000 0000 000000 0
Pitango Venture Capital Venture Capital Minority 000 0000 000000 0
Heznek Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »